J. Won

Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates

Cameron R. Wolfe, M. Hudgens, R. Baric, 2021, medRxiv.

Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice

R. Baric, T. Sheahan, R. Mackman, 2022, Science Translational Medicine.

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

R. Baric, T. Sheahan, R. Mackman, 2021, bioRxiv.

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates.

M. Hudgens, R. Baric, Myron S. Cohen, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

R. Baric, R. Jordan, T. Sheahan, 2020, Nature Communications.

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

R. Baric, T. Sheahan, Rachel L. Graham, 2019, Antiviral Research.

Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice

Martin T. Ferris, J. Bukh, C. Linnertz, 2023, bioRxiv.

Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates

Cameron R. Wolfe, M. Hudgens, R. Baric, 2021, medRxiv.